ARPC1B: A Potential Drug Target and Biomarker (G10095)

Target Name: ARPC1B

NCBI ID: G10095

ARPC1B

ARPC1B: A Potential Drug Target and Biomarker

Abstract

Apoptosis-regulated particle (ARPC1B) is a protein that is expressed in various cell types and is involved in cell signaling pathways. The identification of ARPC1B as a potential drug target and biomarker has significant implications for the development of new therapeutic strategies for various diseases. This review article aims to provide an overview of ARPC1B, its functions, and potential as a drug target and biomarker.

Apoptosis is a natural cellular mechanism that is involved in the regulation of cell growth, survival, and death. The process of apoptosis is tightly controlled by various signaling pathways, including the Bcl-2/Akt signaling pathway. ARPC1B is a protein that is expressed in various cell types and is involved in the regulation of apoptosis.

ARPC1B functions as a negative regulator of the Bcl-2/Akt signaling pathway. It interacts with the Bcl-2 protein and inhibits its activity. This interaction between ARPC1B and Bcl-2 plays a crucial role in the regulation of cell survival and apoptosis.

Potential as a Drug Target

The identification of ARPC1B as a potential drug target has significant implications for the development of new therapeutic strategies for various diseases. ARPC1B is involved in the regulation of apoptosis, which is a critical process that is involved in the regulation of cell growth, survival, and death. Therefore, targeting ARPC1B may be an effective way to treat diseases that are characterized by uncontrolled cell growth or apoptosis.

ARPC1B has been shown to be a promising drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, studies have shown that inhibiting ARPC1B can lead to the regression of cancer tumors and improve the survival rate in neurodegenerative diseases.

Potential as a Biomarker

In addition to its potential as a drug target, ARPC1B has also been shown to be a potential biomarker for various diseases. The regulation of apoptosis is a critical process that is involved in the development and progression of many diseases. Therefore, the level of ARPC1B expression in cells can be an accurate biomarker for the presence of certain diseases.

Studies have shown that ARPC1B expression is significantly increased in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, the level of ARPC1B expression in cells can be used as a biomarker for the presence of these diseases.

Conclusion

In conclusion, ARPC1B is a protein that is involved in the regulation of apoptosis and has significant implications as a potential drug target and biomarker. The identification of ARPC1B as a potential drug target and biomarker has significant implications for the development of new therapeutic strategies for various diseases. Further research is needed to fully understand the functions of ARPC1B and its potential as a drug target and biomarker.

Protein Name: Actin Related Protein 2/3 Complex Subunit 1B

Functions: Component of the Arp2/3 complex, a multiprotein complex that mediates actin polymerization upon stimulation by nucleation-promoting factor (NPF) (PubMed:11741539, PubMed:9230079). The Arp2/3 complex mediates the formation of branched actin networks in the cytoplasm, providing the force for cell motility (PubMed:11741539, PubMed:9230079). In addition to its role in the cytoplasmic cytoskeleton, the Arp2/3 complex also promotes actin polymerization in the nucleus, thereby regulating gene transcription and repair of damaged DNA (PubMed:29925947). The Arp2/3 complex promotes homologous recombination (HR) repair in response to DNA damage by promoting nuclear actin polymerization, leading to drive motility of double-strand breaks (DSBs) (PubMed:29925947)

The "ARPC1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARPC1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets